van der Graaf Y - Search Results

1

The combined use of aspirin, a statin, and blood pressure-lowering agents (polypill components) and the risk of vascular morbidity and mortality in patients with coronary artery disease.

Lafeber M, Spiering W, van der Graaf Y, Nathoe H, Bots ML, Grobbee DE, Visseren FL. Lafeber M, et al. Among authors: van der graaf y. Am Heart J. 2013 Aug;166(2):282-289.e1. doi: 10.1016/j.ahj.2013.04.011. Epub 2013 Jun 15. Am Heart J. 2013. PMID: 23895811

2

Aspirin for primary prevention of vascular events in women: individualized prediction of treatment effects.

Dorresteijn JA, Visseren FL, Ridker PM, Paynter NP, Wassink AM, Buring JE, van der Graaf Y, Cook NR. Dorresteijn JA, et al. Among authors: van der graaf y. Eur Heart J. 2011 Dec;32(23):2962-9. doi: 10.1093/eurheartj/ehr423. Epub 2011 Nov 16. Eur Heart J. 2011. PMID: 22090661 Free PMC article. Clinical Trial.

3

The combined use of aspirin, a statin, and blood pressure-lowering agents (polypill components) in clinical practice in patients with vascular diseases or type 2 diabetes mellitus.

Lafeber M, Grobbee DE, Spiering W, van der Graaf Y, Bots ML, Visseren FL; SMART Study Group. Lafeber M, et al. Among authors: van der graaf y. Eur J Prev Cardiol. 2013 Oct;20(5):771-8. doi: 10.1177/2047487312449587. Epub 2012 May 30. Eur J Prev Cardiol. 2013. PMID: 22649123

4

Hypertensive target organ damage and the risk for vascular events and all-cause mortality in patients with vascular disease.

Vernooij JW, van der Graaf Y, Nathoe HM, Bemelmans RH, Visseren FL, Spiering W. Vernooij JW, et al. Among authors: van der graaf y. J Hypertens. 2013 Mar;31(3):492-99; discussion 499-500. doi: 10.1097/HJH.0b013e32835cd3cd. J Hypertens. 2013. PMID: 23303394

5

The risk of resting heart rate on vascular events and mortality in vascular patients.

Bemelmans RH, van der Graaf Y, Nathoe HM, Wassink AM, Vernooij JW, Spiering W, Visseren FL; SMARTStudy Group. Bemelmans RH, et al. Among authors: van der graaf y. Int J Cardiol. 2013 Sep 30;168(2):1410-5. doi: 10.1016/j.ijcard.2012.12.043. Epub 2013 Jan 8. Int J Cardiol. 2013. PMID: 23305859

6

High-dose statin therapy in patients with stable coronary artery disease: treating the right patients based on individualized prediction of treatment effect.

Dorresteijn JA, Boekholdt SM, van der Graaf Y, Kastelein JJ, LaRosa JC, Pedersen TR, DeMicco DA, Ridker PM, Cook NR, Visseren FL. Dorresteijn JA, et al. Among authors: van der graaf y. Circulation. 2013 Jun 25;127(25):2485-93. doi: 10.1161/CIRCULATIONAHA.112.000712. Epub 2013 May 14. Circulation. 2013. PMID: 23674398

7

The impact of susceptibility loci for coronary artery disease on other vascular domains and recurrence risk.

Tragante V, Doevendans PA, Nathoe HM, van der Graaf Y, Spiering W, Algra A, de Borst GJ, de Bakker PI, Asselbergs FW; SMART study group. Tragante V, et al. Among authors: van der graaf y. Eur Heart J. 2013 Oct;34(37):2896-904. doi: 10.1093/eurheartj/eht222. Epub 2013 Jul 4. Eur Heart J. 2013. PMID: 23828831

8

Low high-density lipoprotein cholesterol is not a risk factor for recurrent vascular events in patients with vascular disease on intensive lipid-lowering medication.

van de Woestijne AP, van der Graaf Y, Liem AH, Cramer MJ, Westerink J, Visseren FL; SMART Study Group. van de Woestijne AP, et al. Among authors: van der graaf y. J Am Coll Cardiol. 2013 Nov 12;62(20):1834-41. doi: 10.1016/j.jacc.2013.04.101. Epub 2013 Aug 21. J Am Coll Cardiol. 2013. PMID: 23948286 Free article.

9

LDL-c-linked SNPs are associated with LDL-c and myocardial infarction despite lipid-lowering therapy in patients with established vascular disease.

van de Woestijne AP, van der Graaf Y, de Bakker PI, Asselbergs FW, de Borst GJ, Algra A, Spiering W, Visseren FL; SMART Study Group. van de Woestijne AP, et al. Among authors: van der graaf y. Eur J Clin Invest. 2014 Feb;44(2):184-91. doi: 10.1111/eci.12206. Epub 2013 Dec 16. Eur J Clin Invest. 2014. PMID: 24251769

10

Personalized cardiovascular disease prevention by applying individualized prediction of treatment effects.

van der Leeuw J, Ridker PM, van der Graaf Y, Visseren FL. van der Leeuw J, et al. Among authors: van der graaf y. Eur Heart J. 2014 Apr;35(13):837-43. doi: 10.1093/eurheartj/ehu004. Epub 2014 Feb 9. Eur Heart J. 2014. PMID: 24513790

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

641 results

Search Page